78 results on '"Owen, Andrew"'
Search Results
2. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz
3. Multidetector (64+) Computed Tomography Angiography of the Lower Limb in Symptomatic Peripheral Arterial Disease: Assessment of Image Quality and Accuracy in a Tertiary Care Setting
4. Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs
5. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
6. Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients
7. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake
8. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment
9. Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation
10. Comprehensive quantification of tablets with multiple active pharmaceutical ingredients using transmission Raman spectroscopy—A proof of concept study
11. Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV
12. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
13. Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
14. A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication
15. Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a ‘mixed matrix’
16. Publish rates of health gain resulting from treatment
17. Special issue of BJP on Nanomedicine
18. The application of nanotechnology in medicine: treatment and diagnostics
19. Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
20. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients
21. New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents
22. The real reasons for measuring patient reported outcomes
23. KHA-CARI Guideline: Vascular access – central venous catheters, arteriovenous fistulae and arteriovenous grafts
24. Life expectancy of elderly and very elderly patients with chronic heart failure
25. Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
26. Predicting intestinal absorption of raltegravir using a population-based ADME simulation
27. Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients
28. Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
29. Transport of gabapentin by LAT1 (SLC7A5)
30. Research Spotlight: Nanomedicines for HIV therapy
31. Interpreting arterial blood gas results
32. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding
33. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg
34. Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies
35. Lamotrigine is a substrate for OCT1 in brain endothelial cells
36. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
37. Apixaban in Patients with Atrial Fibrillation
38. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
39. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort
40. TOWARD GREENER DIALYSIS: A CASE STUDY TO ILLUSTRATE AND ENCOURAGE THE SALVAGE OF REJECT WATER
41. Benefits of cooperation
42. Cardiac-Resynchronization Therapy
43. The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes
44. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes
45. Intracellular ‘boosting’ of darunavir using known transport inhibitors in primary PBMC
46. Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism
47. Is the finding of the PROFESS study consistent with predictions of network meta-analysis?
48. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
49. What is the level of evidence for combined cardiac resynchronization and defibrillation therapy in heart failure?
50. What is the level of evidence for combined cardiac resynchronization and defibrillation therapy in heart failure?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.